Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH1 | P35367 | 2/20 | 0.55 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.55 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.55 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.55 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.55 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.55 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.55 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.55 |
| ▸ | CACNA1D | Q01668 | 1/20 | 0.55 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.55 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.55 |
| ▸ | CACNA1S | Q13698 | 1/20 | 0.55 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.55 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.55 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.55 |
| ▸ | MTOR | P42345 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | GRM7 | Q14831 | 1/20 | 0.46 |
| ▸ | AKT1 | P31749 | 2/20 | 0.46 |
| ▸ | TSHR | P16473 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13900835 | 0.88 | AKT1 (0.63) | HRH1CACNA1FCHRM2CHRM1ADRA2B | |
| SCHEMBL14176512 | 0.80 | HRH1 (0.55) | HRH1CACNA1FCHRM2CHRM1ADRA2B | |
| SCHEMBL28288447 | 0.80 | HRH1 (0.55) | HRH1CACNA1FCHRM2CHRM1ADRA2B | |
| SCHEMBL2622208 | 0.78 | CHRM2 (0.59) | HRH1CACNA1FCHRM2CHRM1ADRA2B | |
| SCHEMBL2622209 | 0.78 | CHRM2 (0.59) | HRH1CACNA1FCHRM2CHRM1ADRA2B | |
| SCHEMBL8260622 | 0.78 | CHRM2 (0.59) | HRH1CACNA1FCHRM2CHRM1ADRA2B | |
| SCHEMBL10426198 | 0.76 | CACNA1F (0.52) | HRH1CACNA1FCHRM2CHRM1ADRA2B | |
| SCHEMBL27168294 | 0.76 | LMNA (0.43) | SLC6A4TSHRKMT2AMAPTLMNA | |
| SCHEMBL2910676 | 0.76 | LMNA (0.43) | SLC6A4TSHRKMT2AMAPTLMNA | |
| SCHEMBL11525874 | 0.76 | SLC6A4 (0.43) | HRH1CACNA1FCHRM2CHRM1ADRA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0781287-B1 | METAL (III) COMPLEXES CONTAINING, NON-AROMATIC, ANIONIC, DIENYL GROUPS AND ADDITION POLYMERIZATION CATALYSTS THEREFROM | DOW CHEMICAL CO (US) | 2002-01-02 | — | — | EP | claimed |
| US-11731943-B2 | Therapeutic compounds, compositions and methods of use thereof | GENENTECH, INC. (US) | 2023-08-22 | — | — | US | disclosed |
| US-11731943-B2 | Therapeutic compounds, compositions and methods of use thereof | GENENTECH, INC. (US) | 2023-08-22 | — | — | US | disclosed |
| US-20210179564-A1 | THERAPEUTIC COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2021-06-17 | — | — | US | disclosed |
| US-10745386-B2 | Coumarin based HSP90 inhibitors with urea and ether substituents | UNIVERSITY OF KANSAS (US) | 2020-08-18 | — | — | US | disclosed |
| US-20190071404-A1 | THERAPEUTIC COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2019-03-07 | — | — | US | disclosed |
| US-20190023698-A1 | COUMARIN BASED HSP90 INHIBITORS WITH UREA AND ETHER SUBSTITUENTS | UNIVERSITY OF KANSAS (US) | 2019-01-24 | — | — | US | disclosed |
| US-10030006-B2 | Coumarin based Hsp90 inhibitors with urea and ether substituents | UNIVERSITY OF KANSAS (US) | 2018-07-24 | — | — | US | disclosed |
| US-20170037010-A1 | COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT | ARDELYX, INC. | 2017-02-09 | — | — | US | disclosed |
| US-20170037010-A1 | COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT | ARDELYX, INC. | 2017-02-09 | — | — | US | disclosed |
| US-20130274278-A1 | IAP INHIBITORS | TETRALOGIC PHARM CORP (US) | 2013-10-17 | — | — | US | disclosed |
| US-8481495-B2 | IAP inhibitors | TETRALOGIC PHARMACEUTICALS CORPORATION (US) | 2013-07-09 | — | — | US | disclosed |
| US-8481495-B2 | IAP inhibitors | TETRALOGIC PHARMACEUTICALS CORPORATION (US) | 2013-07-09 | — | — | US | disclosed |
| US-8461209-B2 | Malonic acid sulfonamide derivative and pharmaceutical use thereof | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2013-06-11 | — | — | US | disclosed |
| US-8461209-B2 | Malonic acid sulfonamide derivative and pharmaceutical use thereof | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2013-06-11 | — | — | US | disclosed |
| US-20130018207-A1 | Frustrated Lewis Pair Compositions | STEPHAN CONSULTING CORPORATION (CA) | 2013-01-17 | — | — | US | disclosed |
| US-20120094917-A1 | IAP INHIBITORS | TETRALOGIC PHARMACEUTICALS CORP (US) | 2012-04-19 | — | — | US | disclosed |
| US-20100228026-A1 | NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2010-09-09 | — | — | US | disclosed |
| US-20100228026-A1 | NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2010-09-09 | — | — | US | disclosed |
| US-7504391-B2 | Selective D1/D5 receptor antagonists for the treatment of obesity and CNS disorders | SCHERING CORPORATION (US) | 2009-03-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130018207-A1 | Frustrated Lewis Pair Compositions | LPAR3, SSTR3, LPAR1 | HRH1 1293/4885CACNA1F 3881/4885CHRM2 406/4885 |
| US-10745386-B2 | Coumarin based HSP90 inhibitors with urea and ether substituents | HSP90B1, HSP90AA1, HSP90AB1 | HRH1 1488/4885CACNA1F 4873/4885CHRM2 3948/4885 |
| US-20190071404-A1 | THERAPEUTIC COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | JAK2, JAK1, JAK3 | HRH1 2640/4885CACNA1F 4119/4885CHRM2 4823/4885 |
| US-20170037010-A1 | COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT | SLC34A2, SLC34A1, SLC10A2 | HRH1 2053/4885CACNA1F 1056/4885CHRM2 3200/4885 |
| US-10030006-B2 | Coumarin based Hsp90 inhibitors with urea and ether substituents | HSP90B1, HSP90AA1, HSP90AB1 | HRH1 1416/4885CACNA1F 4875/4885CHRM2 3848/4885 |
| US-20130274278-A1 | IAP INHIBITORS | XIAP, IAPP, BIRC5 | HRH1 3728/4885CACNA1F 3445/4885CHRM2 4448/4885 |
| US-11731943-B2 | Therapeutic compounds, compositions and methods of use thereof | JAK2, JAK1, JAK3 | HRH1 2640/4885CACNA1F 4119/4885CHRM2 4823/4885 |
| US-20210179564-A1 | THERAPEUTIC COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | JAK2, JAK1, JAK3 | HRH1 2640/4885CACNA1F 4119/4885CHRM2 4823/4885 |
| US-20100228026-A1 | NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF | REN, AGTR2, AGTR1 | HRH1 675/4885CACNA1F 1002/4885CHRM2 1595/4885 |
| US-20190023698-A1 | COUMARIN BASED HSP90 INHIBITORS WITH UREA AND ETHER SUBSTITUENTS | HSP90B1, HSP90AA1, HSP90AB1 | HRH1 1416/4885CACNA1F 4875/4885CHRM2 3848/4885 |
| US-20120094917-A1 | IAP INHIBITORS | XIAP, IAPP, BIRC5 | HRH1 3728/4885CACNA1F 3445/4885CHRM2 4448/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.